Atlas Trials

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

Clinical trial NCT07168317 · RECRUITING

Trial details

NCT number
NCT07168317
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
New Diagnosed Angioimmunoblastic T-Cell Lymphoma
Start date
2025-08-01
Primary completion
2028-08-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.